Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Drug Profile

Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 06 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation; Miyazaki University School of Medicine
  • Class Antihyperglycaemics; Cardiovascular therapies; Glucosides; Heart failure therapies; Obesity therapies; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Heart failure; Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 30 Jan 2019 Hiroshima University Hospital and Mitsubishi Tanabe Pharma Corporation complete a clinical trial for Type 2 diabetes mellitus in Japan (UMIN000024667)
  • 28 Jan 2019 Mitsubishi Tanabe Pharma Corporation and Miyazaki University School of Medicine completes a phase II trial Type 2 diabetes mellitus in Japan (UMIN000030043)
  • 30 Oct 2018 The US FDA approves canagliflozin to reduce the risk of major adverse cardiovascular events, composed of cardiovascular death, myocardial infarction and stroke, in adults with type II diabetes mellitus who have established cardiovascular disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top